Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
General transcription factor IIE subunit 2 (GTF2E2) encodes the beta subunit of the TFIIE complex, a critical element of the RNA polymerase II transcription initiation machinery[1][3][5]. TFIIE (a heterodimer of alpha and beta subunits) is required for recruiting TFIIH and enabling promoter clearance, thus allowing transcription to move from initiation to elongation. The beta subunit, encoded by GTF2E2, facilitates conformational changes and stimulates the XPB helicase in TFIIH to promote promoter opening and efficient transcriptional initiation[1][3]. Mutations in GTF2E2 underlie nonphotosensitive trichothiodystrophy (TTD6) and have been mapped to regions of genetic diseases. Aberrant overexpression has been linked to certain cancers and is implicated in cell proliferation via pathways such as AKT/ERK/mTOR[1]. GTF2E2 has also been functionally tied to the HIV life cycle and is involved in basal cellular transcriptional regulation across many tissues[3][5]. There are no currently approved targeted drugs or therapeutics for GTF2E2, though its disease associations and biomarker potential are subjects of ongoing research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on General transcription factor IIE subunit 2 (GTF2E2).